科源制药
(301281)
| 流通市值：18.23亿 | | | 总市值：31.57亿 |
| 流通股本：6255.20万 | | | 总股本：1.08亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 146,276,963.82 | 447,583,620.32 | 340,680,063.3 | 224,474,771.8 |
| 营业收入 | 146,276,963.82 | 447,583,620.32 | 340,680,063.3 | 224,474,771.8 |
| 二、营业总成本 | 124,459,548.73 | 381,057,260.02 | 276,619,313.03 | 172,912,864.87 |
| 营业成本 | 85,598,444.16 | 236,091,946.9 | 170,832,640.75 | 106,244,871.47 |
| 税金及附加 | 1,566,297.03 | 4,843,312.46 | 3,723,429.55 | 2,684,714.18 |
| 销售费用 | 20,930,375.42 | 63,399,885.46 | 45,425,247.33 | 31,085,802.31 |
| 管理费用 | 8,510,046.78 | 37,710,815.03 | 30,111,343.78 | 20,462,144.98 |
| 研发费用 | 8,784,714.8 | 43,859,260.03 | 29,830,782.38 | 15,461,127.25 |
| 财务费用 | -930,329.46 | -4,847,959.86 | -3,304,130.76 | -3,025,795.32 |
| 其中:利息收入 | 1,276,190.62 | 3,769,045.21 | 2,937,952.98 | 1,836,419.07 |
| 加:公允价值变动收益 | 1,017,373.16 | 543,183.1 | 4,229,880.21 | 432,601.82 |
| 加:投资收益 | 540,743.96 | 12,201,059.45 | 1,674,693.95 | 348,612.54 |
| 资产处置收益 | - | 345,993.55 | 11,482.86 | 11,482.86 |
| 资产减值损失(新) | -2,840.7 | -3,377,172.45 | -97,653.11 | -97,653.11 |
| 信用减值损失(新) | -1,703,932.59 | -115,012.21 | -659,656.47 | 469,557.72 |
| 其他收益 | 2,759,649.86 | 3,992,164.91 | 2,468,390.45 | 1,905,615.65 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 24,428,408.78 | 80,116,576.65 | 71,687,888.16 | 54,632,124.41 |
| 加:营业外收入 | - | 313,368.13 | 234,544.23 | 138,319.45 |
| 减:营业外支出 | 1,199,361.42 | 694,887.06 | 579,513.88 | 282,640.33 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 23,229,047.36 | 79,735,057.72 | 71,342,918.51 | 54,487,803.53 |
| 减:所得税费用 | 1,705,284.3 | 2,695,618.57 | 4,788,088.99 | 3,283,358.65 |
| 六、净利润 | 21,523,763.06 | 77,039,439.15 | 66,554,829.52 | 51,204,444.88 |
| 持续经营净利润 | 21,523,763.06 | 77,039,439.15 | 66,554,829.52 | 51,204,444.88 |
| 归属于母公司股东的净利润 | 21,532,537.03 | 77,039,439.15 | 66,554,829.52 | 51,204,444.88 |
| 少数股东损益 | -8,773.97 | - | - | - |
| (一)基本每股收益 | 0.2 | 0.76 | 0.67 | 0.54 |
| (二)稀释每股收益 | 0.2 | 0.76 | 0.67 | 0.54 |
| 九、综合收益总额 | 21,523,763.06 | 77,039,439.15 | 66,554,829.52 | 51,204,444.88 |
| 归属于母公司股东的综合收益总额 | 21,532,537.03 | 77,039,439.15 | 66,554,829.52 | 51,204,444.88 |
| 归属于少数股东的综合收益总额 | -8,773.97 | - | - | - |
| 公告日期 | 2024-04-22 | 2024-03-29 | 2023-10-26 | 2023-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |